Fenretinide and cancer prevention

Area of Science:

• Oncology
• Pharmacology
• Cancer Chemoprevention

Background:

• Fenretinide is known to inhibit cell growth via apoptosis, with both receptor-dependent and -independent mechanisms.
• Its chemopreventive efficacy has been explored in clinical trials across various organs.

Purpose of the Study:

• To evaluate the efficacy of fenretinide in preventing secondary malignancies and new occurrences of certain conditions.
• To assess the impact of fenretinide on specific cancer types and precancerous lesions.

Main Methods:

• Clinical trials were conducted to investigate fenretinide's effects on different organs.
• A phase III secondary prevention trial focused on early breast cancer patients.
• Studies also examined fenretinide's impact on ovarian cancer, leukoplakia, and superficial bladder tumors.

Main Results:

• A phase III trial suggested fenretinide benefits premenopausal women by preventing second breast malignancies.
• Clinical trials indicated potential benefits for ovarian cancer and a reduction in leukoplakia occurrences.
• No significant effects were observed on urothelial cells or recurrence rates in superficial bladder tumor patients.

Conclusions:

• Fenretinide demonstrates chemopreventive potential, particularly in secondary breast cancer prevention.
• Further research, potentially using surrogate biomarkers, is needed to fully evaluate fenretinide's efficacy across targeted organs.